Biotech Growth Trust (The) (LSE:BIOG) Piotroski F-Score: 4 (As of Jul. 16, 2026) — 20% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BIOG Biotech Growth Trust (The) PLC LSE:BIOG
39 GF Score
Price £15.90
! 2 Warning Signs
View Full Analysis

What is Biotech Growth Trust (The) Piotroski F-Score?

Biotech Growth Trust (The) LSE:BIOG -0.62% 39 Piotroski F-Score is 4 as of Jul. 16, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates LSE:BIOG with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 1,593 Asset Management companies, Biotech Growth Trust (The) ranks worse than 57.25% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biotech Growth Trust (The) has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Biotech Growth Trust (The)'s Piotroski F-Score or its related term are showing as below:

LSE:BIOG' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 6
Current: 4

During the past 13 years, the highest Piotroski F-Score of Biotech Growth Trust (The) was 6. The lowest was 2. And the median was 5.

Biotech Growth Trust (The)  (LSE:BIOG) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biotech Growth Trust (The) Piotroski F-Score Related Terms


Biotech Growth Trust (The) Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Biotech Growth Trust (The)'s Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotech Growth Trust (The) Piotroski F-Score Chart

Biotech Growth Trust (The) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 6.00 4.00 5.00 4.00

Biotech Growth Trust (The) Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 5.00 0.00 4.00

LSE:BIOG vs BLK, BX, KKR: Piotroski F-Score Comparison

For the Asset Management subindustry, Biotech Growth Trust (The)'s Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotech Growth Trust (The) Piotroski F-Score vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Biotech Growth Trust (The)'s Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Biotech Growth Trust (The)'s Piotroski F-Score falls into.


LSE:BIOG
39GF Score
Biotech Growth Trust (The) PLC LSE:BIOG
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was £130.3 Mil.
Cash Flow from Operations was £-4.8 Mil.
Revenue was £133.9 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (226.629 + 302.246) / 2 = £264.4375 Mil.
Total Assets at the begining of this year (Mar25) was £226.6 Mil.
Long-Term Debt & Capital Lease Obligation was £12.3 Mil.
Total Assets was £302.2 Mil.
Total Liabilities was £20.3 Mil.
Net Income was £-82.7 Mil.

Revenue was £-78.8 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (411.42 + 226.629) / 2 = £319.0245 Mil.
Total Assets at the begining of last year (Mar24) was £411.4 Mil.
Long-Term Debt & Capital Lease Obligation was £0.0 Mil.
Total Assets was £226.6 Mil.
Total Liabilities was £5.4 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biotech Growth Trust (The)'s current Net Income (TTM) was 130.3. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biotech Growth Trust (The)'s current Cash Flow from Operations (TTM) was -4.8. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=130.255/226.629
=0.57474992

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-82.661/411.42
=-0.20091634

Biotech Growth Trust (The)'s return on assets of this year was 0.57474992. Biotech Growth Trust (The)'s return on assets of last year was -0.20091634. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biotech Growth Trust (The)'s current Net Income (TTM) was 130.3. Biotech Growth Trust (The)'s current Cash Flow from Operations (TTM) was -4.8. ==> -4.8 <= 130.3 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=12.319/264.4375
=0.04658568

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/319.0245
=0

Biotech Growth Trust (The)'s gearing of this year was 0.04658568. Biotech Growth Trust (The)'s gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

* Note that for banks and insurance companies, there's no Total Current Assets and Total Current Liabilities reported. Thus, we use Total Assets and Total Liabilities to calculate current ratio for banks and insurance companies.

Current Ratio (This Year: Mar26)=Total Assets/Total Liabilities
=302.246/20.323
=14.87211534

Current Ratio (Last Year: Mar25)=Total Assets/Total Liabilities
=226.629/5.423
=41.79033745

Biotech Growth Trust (The)'s current ratio of this year was 14.87211534. Biotech Growth Trust (The)'s current ratio of last year was 41.79033745. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biotech Growth Trust (The)'s number of shares in issue this year was 23.341. Biotech Growth Trust (The)'s number of shares in issue last year was 31.514. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

* Note that for banks and insurance companies, there's no Gross Profit reported. Thus, we use net income instead of gross profit and calculate Net Margin for this score.

Net Margin (This Year: TTM)=Net Income/Revenue
=130.255/133.859
=0.97307615

Net Margin (Last Year: TTM)=Net Income/Revenue
=-82.661/-78.809
=1.04887767

Biotech Growth Trust (The)'s net margin of this year was 0.97307615. Biotech Growth Trust (The)'s net margin of last year was 1.04887767. ==> Last year's net margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=133.859/226.629
=0.59065256

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=-78.809/411.42
=-0.19155364

Biotech Growth Trust (The)'s asset turnover of this year was 0.59065256. Biotech Growth Trust (The)'s asset turnover of last year was -0.19155364. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+0+0+1+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biotech Growth Trust (The) has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Biotech Growth Trust (The) (LSE:BIOG) has a Piotroski F-Score of 4 as of Jul. 16, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Biotech Growth Trust (The) and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Biotech Growth Trust (The)'s Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Biotech Growth Trust (The) ranks #912 out of 1593 companies in the Asset Management industry, placing it in the top 57.3%.
Is Biotech Growth Trust (The)'s Piotroski F-Score too high?
Biotech Growth Trust (The)'s current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Asset Management industry median Piotroski F-Score is 5.00. Biotech Growth Trust (The)'s value of 4 is 20% below this industry median. Based on the distribution chart, Biotech Growth Trust (The) ranks #912 out of 1593 companies in the Asset Management industry, which is below the industry midpoint. Overall, Biotech Growth Trust (The) has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Biotech Growth Trust (The)'s Piotroski F-Score compare to BLK and BX?
According to the Asset Management industry distribution chart, Biotech Growth Trust (The) ranks #912 out of 1593 companies for Piotroski F-Score. This places Biotech Growth Trust (The) in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Biotech Growth Trust (The)'s value of 4 is 20% below this benchmark. Historically, Biotech Growth Trust (The)'s own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Biotech Growth Trust (The) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for an Asset Management company?
The median Piotroski F-Score among Asset Management companies is 5.00, based on 1,593 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotech Growth Trust (The)'s current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Biotech Growth Trust (The) and its competitors. For the Asset Management industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotech Growth Trust (The)'s current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotech Growth Trust (The) stock overvalued right now?
Biotech Growth Trust (The) (LSE:BIOG) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Asset Management industry median of 5.00. Biotech Growth Trust (The)'s overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Biotech Growth Trust (The) (LSE:BIOG), the current Piotroski F-Score is 4 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotech Growth Trust (The) Business Description

Address 25 Southampton Buildings, London, GBR, WC2A 1AL
Biotech Growth Trust (The) PLC is an externally managed investment trust. Its business objective is to provide its investors with capital appreciation by investing in the biotechnology industry around the world.
39GF Score

Get the complete analysis for LSE:BIOG

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£15.90
Price